摘要
目的对于铂类治疗后进展耐药的进展期尿路上皮癌,目前并无标准有效的治疗方案。本研究意在通过回顾分析白蛋白紫杉醇联合抗血管生成药物在多线治疗后进展期尿路上皮癌的治疗效果,对临床治疗提供一定指导和帮助。方法选取23例进展期尿路上皮癌患者纳入本单臂临床研究。治疗方案:白蛋白紫杉醇联合贝伐单抗或血管内皮抑素。结果 23例患者平均用药周期为3.0周期,2例患者获得PR(8.7%),9例患者获得SD(39.1%),总的疾病控制率(ORR)达21.7%。治疗的中位PFS时间为12.0周。血液学毒性为最常见的不良反应(52.2%)。至随访结束(中位随访时间7.0月),22例患者死亡,中位生存时间7.0月。结论白蛋白紫杉醇联合抗血管生成药物在多线治疗后进展期尿路上皮癌中有一定的治疗效果。该方案在进展期尿路上皮癌二线治疗中的疗效,尚需大样本临床研究进一步确认。
Objective The treatment of patients with recurrent advanced transitional cell carcinoma of the urotheliumthat progressed after prior platinum-based chemotherapy remains an unmet clinical need. This study assessed the antitumor activity of paclitaxel-albuminplus anti-angiogenesisas no- first- line treatment in patients with advanced transitional cell carcinoma of the urothelium, retrospectively. Methods 23 patients with advanced transitional cell carcinoma of the urothelium were enrolled this single arm study. Patients received paclitaxel-albuminplus anti-angiogenesis(Bevacizumabor Endostatin) treatment. Results The mean treatment of 23 patients were 3.0 cycles. 2 patients had partial response(8.7%), 9 patients had stable disease(39.1%). Overall response rate (ORR) was 21.7%. Median progression-free survival was 12.0 weeks.Hematologic leukopenia was the most common toxicity(52.2%). Until last follow up (median follow-up time 7.0 months), 22 patients dead. Median overall survival was 7.0 months. Conclusion Paclitaxel-albuminplus anti-angiogenesisis safe and active as no-first-line treatment in patients with advanced transitional cell carcinoma of the urothelium. Additional evaluation is still warranted.
作者
王轩
斯璐
毛丽丽
迟志宏
盛锡楠
崔传亮
孔燕
唐碧霞
鄢谢桥
郭军
Wang Xuan;Si Lu;Mao Li-li;Chi Zhi-hong;Sheng Xi-nan;Cui Chuan-liang;Kong Yan;Tang Bi-xia;Yan Xie-qiao;Guo Jun(Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China)
出处
《当代医学》
2017年第10期35-38,共4页
Contemporary Medicine
关键词
尿路上皮癌
二线治疗
抗血管生成药物
Transitional cell carcinoma of the urothelium
Sencond-line treatment
anti-angiogenesis
